Royalty Pharma Increases Its Bid for Elan to $7.3B

Sheridan, Cormac
April 2013
BioWorld International;4/17/2013, Vol. 18 Issue 16, p1
The article reports that Royalty Pharma increased its bid for biotechnology firm Elan Corp. plc to 12 U.S. dollars per share. The increased offer follows a general meeting held by Elan in Dublin, Germany, at which shareholders approved a one billion U.S. dollar share buyback. The author also considers the issues surrounding Royaty Pharma's offer for Elan.


Related Articles

  • Royalty Pharma Increases Its Bid for Elan to $7.3B. Sheridan, Cormac // BioWorld Today;4/16/2013, Vol. 24 Issue 72, p3 

    The article reports on Royalty Pharma's increase of its per-share bid for Irish biotechnology and pharmaceutical company Elan Corp. PLC in an offer that values the latter at approximately 7.3 billion dollars. An extraordinary general meeting held by Elan on April 12, 2013 at which shareholders...

  • Royalty Pharma Bids $6.6B For Elan, but Is it a Fair Offer? Sheridan, Cormac // BioWorld Today;2/26/2013, Vol. 24 Issue 37, p1 

    The article reports on the $11 per-share takeover offered by Royalty Pharma AG to Dublin, Ireland-based Elan Corp. PLC. Leerink Swank analyst Marko Kozul recommends that shareholders accept the proposal as is because he believes that risk in Elan will move forward with merger and acquisition or...

  • Royalty Pharma Bids $6.6B For Elan, but Is It a Fair Offer? Sheridan, Cormac // BioWorld International;2/27/2013, Vol. 18 Issue 9, p1 

    The article reports on the five percent increase in Elan Corp. PLC's shares which is a response to the $11 per-share takeover offered by Royalty Pharma. It says that Elan has an alternative strategic to consider for the bid offered by Royalty Pharma. Richard Parkes, Deutsche Bank's analyst,...

  • Royalty Pharma Raises Elan Offer to at Least $6.7B. Kitamura, Makiko // Mergers & Acquisitions Report;6/10/2013, Vol. 26 Issue 23, p44 

    The article reports on the decision of Irish pharmaceutical firm Royalty Pharma to increase its acquisition offer to biotechnology company Elan Corp. in 2013. It mentions that the offer of Royalty Pharma was raised by five per cent and reached 6.7 billion U.S. dollars. According to the author,...

  • Elan Faces Hostile Bid from Royalty Pharma.  // MondayMorning;4/22/2013, Vol. 21 Issue 15, p1 

    The article focuses on takeover bidding offer from Royalty Pharma AG, an investor in royalty streams from pharmaceuticals, to buy Elan Corp. PLC. It mentions that Royalty Pharma has raised its offer to U.S. dollars 7.3 billion. It mentions shareholders of Elan Corp. PLC will be enable to avoid...

  • Elan Collapses on Accounting Fears.  // Chemical Market Reporter;2/11/2002, Vol. 261 Issue 6, p3 

    Reports on several controversies faced by Elan Corp. PLC. Percentage of decline in stock price of the company in February 5, 2002; Information on a shareholder lawsuit faced by the company; Sales projection of the company for 2002.

  • Elan Looks East with 2 Deals As Royalty Revises Hostile Bid. Sheridan, Cormac // BioWorld International;5/22/2013, Vol. 18 Issue 21, p1 

    The article reports that Irish drug company Elan Corp. PLC is continuing its merger and acquisition (M&A) strategy despite facing a hostile bid from Royalty Pharma. Elan is buying AOP Pharmaceuticals AG and is also planning to acquire a stake in Newbridge Pharmaceuticals FZ-LLC. Royalty Pharma...

  • Decision Time Looms for Elan, Royalty in Bitter Takeover Battle. Sheridan, Cormac // BioWorld Today;6/11/2013, Vol. 24 Issue 111, p1 

    The article reports that Elan Corp. PLC shareholders are scheduled to vote on the company's merger and acquisition (M&A) deal with Royalty Pharma. The M&A deal requires a vote representing 50 percent of Elan's equity plus one share. Royalty has submitted a revised offer in advance of the vote,...

  • Ashurst joins US and Irish firms as Elan rejects Royalty Pharma bid. Harris, Joanne // Lawyer (Online Edition);4/23/2013, p10 

    The article offers information on the failure of an attempt by biopharmaceutical Royalty Pharma AG to acquire Irish biotechnology company Elan. Elan defended Royalty Pharma AG's bid by turning to law firms A&L Goodbody LLC and Cadwalader Wickersham & Taft LLP. Recently 50 percent stake of Elan...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics